Study of MK-3475 (Pembrolizumab) in Participants With Advanced Melanoma (MK-3475-041)

This study will assess the safety, tolerability, and efficacy of every-3-week dosing (Q3W) of pembrolizumab in participants with advanced melanoma; participants may receive pembrolizumab for up to 2 years if deriving clinical benefit. The primary study hypothesis is that treatment with single agent pembrolizumab will result in a clinically meaningful overall response rate.


Study Type: Interventional
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Primary Purpose: Treatment
Official Title: Phase Ib Study of MK-3475 in Subjects With Advanced Melanoma
Estimated Enrollment: 35
Study Start Date: July 2014
Estimated Study Completion Date: March 2017
Estimated Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)

Arms:
- Experimental: Pembrolizumab